A novel molecule "shati" is involved in methamphetamine-induced hyperlocomotion, sensitization, and conditioned place preference

Journal of Neuroscience

Volumn 27, Issue 28, 2007, Pages 7604-7615

  Niwa, Minae ^a,b   Nitta, Atsumi ^a   Mizoguchi, Hiroyuki ^a   Ito, Yasutomo ^a   Noda, Yukihiro ^a   Nagai, Taku ^a   Nabeshima, Toshitaka ^a,b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Addiction; Behavioral sensitization; Conditioned place preference; Dopamine; Methamphetamine; Shati

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; DOPAMINE RECEPTOR; MESSENGER RNA; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DNA DETERMINATION; DOPAMINE UPTAKE; DOSE RESPONSE; LOCOMOTION; MALE; MESENCEPHALON; METHODOLOGY; MOLECULE; MOUSE; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PLACE PREFERENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTOSOME;

ACETYLTRANSFERASES; AMINO ACID SEQUENCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CONDITIONING (PSYCHOLOGY); DOPAMINE; DYSKINESIA, DRUG-INDUCED; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 34447544385     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1575-07.2007     Document Type: Article

References (64)

1. Ang E, Chen J, Zagouras P, Magna H, Holland J, Schaeffer E, Nestler EJ (2001) Induction of nuclear factor-κB in nucleus accumbens by chronic cocaine administration. J Neurochem 79:221-224.
2. Blackshaw S, Harpavat S, Trimarchi J., Cai L, Huang H, Kuo WP, Weber G, Lee K, Fraioli RE, Cho SH, Yung R, Asch E, Ohno-Machado L, Wong WH, Cepko CL (2004) Genomic analysis of mouse retinal development. PLoS Biol 2:E247.
3. Bowers MS, McFarland K, Lake RW, Peterson YK, Lapish CC, Gregory ML, Lanier SM, Kalivas PW (2004) Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron 42:269-281.
4. Carlezon Jr WA, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, Duman RS, Neve RL, Nestler EJ (1998) Regulation of cocaine reward by CREB. Science 282:2272-2275.
5. Cha XY, Pierce RC, Kalivas PW, Mackler SA (1997) NAC-1, a rat brain mRNA, is increased in the nucleus accumbens three weeks after chronic cocaine self-administration. J Neurosci 17:6864-6871.
6. Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529-1540.
7. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD (1996) Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 93:6025-6030.
8. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
9. Douglass J, Daoud S (1996) Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. Gene 169:241-245.
10. 3H]dopamine accumulation by synaptic vesicles purified from rat striatum: inhibition by thiocyanate ion. Brain Res 516:155-160.
11. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834-838.
12. Flores C, Samaha AN, Stewart J (2000) Requirement of endogenous basic fibroblast growth factor for sensitization to amphetamine. J Neurosci 20:RC55(1-5).
13. Franklin KBJ, Paxinos G (1997) The mouse brain: in stereotaxic coordinates. San Diego: Academic.
14. Giros B, Jaber M, Jones SR, Wightman PM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
15. Gurskaya NG, Diatchenko L, Chenchik A, Siebert PD, Khaspekov GL, Lukyanov KA, Vagner LL, Ermolaeva OD, Lukyanov SA, Sverdlov ED (1996) Equalizing cDNA subtraction based on selective suppression of polymerase chain reaction: cloning of Jurkat cell transcripts induced by phytohemaglutinin and phorbol 12-myristate 13-acetate. Anal Biochem 240:90-97.
16. Hall FS, Drgonova J, Goeb M, Uhl GR (2003) Reduced behavioral effects of cocaine in heterozygous brain-derived neurotropic factor (BDNF) knockout mice. Neuropsychopharmacology 28:1485-1490.
17. 3H-dopamine in rat brain tissue slices. Biochem Pharmacol 24:847-852.
18. Hiroi N, White NM (1991) The amphetamine conditioned place preference: differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas. Brain Res 552:141-152.
19. Hiroi N, Brown JR, Haile CN, Ye H, Greenberg ME, Nestler EJ (1997) FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA 94:10397-10402.
20. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR (1999) Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotropic factor. J Neurosci 19:4110-4122.
21. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184.
22. Koob GF, Sanna PP, Bloom FE (1998) Neuroscience of addiction. Neuron 21:467-476.
23. Laakso A, Mohn AR, Gainetdinov RR, Caron MG (2002) Experimental genetic approaches to addiction. Neuron 36:213-228.
24. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22:8951-8960.
25. Liu Y, Edwards RH (1997) The role of vesicular transporter proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 20:125-156.
26. Lorrain DS, Arnold GM, Vezina P (2000) Previous exposure to amphetamine increases incentive to obtain the drug: long-lasting effects revealed by the progressive ratio schedule. Behav Brain Res 107:9-19.
27. McClung CA, Nestler EJ (2003) Regulation of gene expression and cocaine reward by CREB and ΔFosB. Nat Neurosci 6:1208-1215.
28. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK (1995) Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274:90-96.
29. Messer CJ, Eisch AJ, Carlezon Jr WA, Whisler K, Shen L, Wolf DH, Westphal H, Collins F, Russell DS, Nestler EJ (2000) Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26:247-257.
30. Mizoguchi H, Yamada K, Mizuno M, Mizuno T, Nitta A, Noda Y, Nabeshima T (2004) Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. Mol Pharmacol 65:1293-1301.
31. Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y, Nabeshima T (2007) Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J Neurochem 100:1579-1588.
32. Nagai T, Yamada K, Yoshimura M, Ishikawa K, Miyamoto Y, Hashimoto K, Noda Y, Nitta A, Nabeshima T (2004) The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 101:3650-3655.
33. Nagai T, Noda Y, Ishikawa K, Miyamoto Y, Yoshimura M, Ito M, Takayanagi M, Takuma K, Yamada K, Nabeshima T (2005a) The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem 92:660-667.
34. Nagai T, Kamei H, Ito M, Hashimoto K, Takuma K, Nabeshima T, Yamada K (2005b) Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, but not anti-nociceptive effect in mice. J Neurochem 93:1272-1279.
35. Nagai T, Ito M, Nakamichi N, Mizoguchi H, Kamei H, Fukakusa A, Nabeshima T, Takuma K, Yamada K (2006) The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci 26:12374-12383.
36. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, He J, Nitta A, Mizuno M, Tran MH, Seto A, Yoshimura M, Kitaichi K, Hasegawa T, Saito K, Yamada Y, Seishima M, Sekikawa K, Kim HC, Nabeshima T (2004) Role of tumor necrosis factor-α in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 24:2212-2225.
37. Napier TC, Givens BS, Schulz DW, Bunney BS, Breese GR, Mailman RB (1986) SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons. J Pharmacol Exp Ther 236:838-845.
38. Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2:119-128.
39. Nestler EJ (2002) From neurobiology to treatment: progress against addiction. Nat Neurosci 5:1076-1079.
40. Niwa M, Nitta A, Shen L, Noda Y, Nabeshima T (2007a) Involvement of glial cell line-derived neurotrophic factor in inhibitory effects of a hydrophobic dipeptide Leu-Ile on morphine-induced sensitization and rewarding effects. Behav Brain Res 179:167-171.
41. Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Shen L, Noda Y, Furukawa S, Nabeshima T (2007b) An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-α protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry 61:890-901.
42. Niwa M, Nitta A, Yamada K, Nabeshima T (2007c) The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-α, and an inducer of these factors in drug dependence. J Pharmacol Sci, in press.
43. Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Noda Y, Nabeshima T (2007d) Tumor necrosis factor-α and its inducer inhibit morphine-induced rewarding effects and sensitization. Biol Psychiatry, in press.
44. Noda Y, Miyamoto Y, Mamiya T, Kamei H, Furukawa H, Nabeshima T (1998) Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. J Pharmacol Exp Ther 286:44-51.
45. Robbins TW, Everitt BJ (1996) Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6:228-236.
46. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247-291.
47. Satel SL, Southwick SM, Gawin FH (1991) Clinical features of cocaine-induced paranoia. Am J Psychiatry 148:495-498.
48. Schechter MD, Calcagnetti DJ (1998) Continued trends in the conditioned place preference literature from 1992 to 1996, inclusive, with a cross-indexed bibliography. Neurosci Biobehav Rev 22:827-846.
49. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677.
50. Strakowski SM, Sax KW (1998) Progressive behavioral response to repeated d-amphetamine challenge: further evidence for sensitization in humans. Biol Psychiatry 44:1171-1177.
51. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F et al. (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 99:16899-16903.
52. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433.
53. Taubenfeld SM, Milekic MH, Monti B, Alberini CM (2001) The consolidation of new but not reactivated memory requires hippocampal C/EBPβ. Nat Neurosci 4:813-818.
54. Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43:555-560.
55. Ujike H, Onoue T, Akiyama K, Hamamura T, Otsuki S (1989) Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 98:89-92.
56. Wada R, Tifft CJ, Proia RL (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 97:10954-10959.
57. Walters CL, Blendy JA (2001) Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse. J Neurosci 21:9438-9444.
58. Wang XB, Funada M, Imai Y, Revay RS, Ujike H, Vandenbergh DJ, Uhl GR (1997) rGβ1: a psychostimulant-regulated gene essential for establishing cocaine sensitization. J Neurosci 17:5993-6000.
59. Wise RA (1996a) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319-340.
60. Wise RA (1996b) Neurobiology of addiction. Curr Opin Neurobiol 6:243-251.
61. Wolf ME (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54:679-720.
62. Yamada K, Nabeshima T (2004) Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction: mini review. Ann NY Acad Sci 1025:198-204.
63. Yan Y, Yamada K, Niwa M, Nagai T, Nitta A, Nabeshima T (2007) Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial cell line-derived neurotrophic factor mutant mice. FASEB J, in press.
64. Zachariou V, Bolanos CA, Selley DE, Theobald D, Cassidy MP, Kelz MB, Shaw-Lutchman T, Berton O, Sim-Selley LJ, Dileone RJ, Kumar A, Nestler EJ (2006) An essential role for ΔFosB in the nucleus accumbens in morphine action. Nat Neurosci 9:205-211.